<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237012</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB Protocol # 20192595</org_study_id>
    <nct_id>NCT04237012</nct_id>
  </id_info>
  <brief_title>ACCURATE Study for Subjects With Dry Eyes</brief_title>
  <acronym>ACCURATE</acronym>
  <official_title>Randomized Self-Controlled Treatment With an Intracanalicular Dexamethasone Insert Compared to Topical Over the Counter Lubrication Therapy in Patients With Bilateral Ocular Surface Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Eye Centers of Racine and Kenosha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Eye Centers of Racine and Kenosha</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine treatment and imaging outcomes in bilateral ocular surface disease management
      with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical
      over-the-counter artificial tears lubrication management
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the benefit of treatment with a physician administered
      intracanalicular dexamethasone insert and patient administered artificial tears prn compared
      to patient administered artificial tears prn (control) in patients with bilateral ocular
      surface dry eye disease. The study is a self-controlled design and includes multiple
      objective, measureable, and quantifiable endpoints to best determine an objective response to
      treatment in patient eyes randomized to either the insert plus prn artificial tears or
      artificial tears prn control. To aid in ensuring best possible masking, DEXTENZA is best
      visualized with blue light and yellow filter and therefore visualization will not be assessed
      until final visit following all measures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine effect of dexamethasone insert over artificial tears</measure>
    <time_frame>1 month</time_frame>
    <description>To determine the effect of dexamethasone insert plus over-the-counter artificial tears prn compared to over the counter artificial tears prn from Baseline at Week 2 (at 8 am, 12 pm and 4 pm) as measured by iTrace and IOL Master 700: and comfort of dry eyes using the OSDI scale and reading scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OSDI scores</measure>
    <time_frame>1 month</time_frame>
    <description>comfort of dry eyes using the OSDI scale and reading scores, scores are from the SPEED questionnaire. scale from 0-3 0-Never 1- Sometime 2-Often 3-Constant for the symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ITRACE</measure>
    <time_frame>1 month</time_frame>
    <description>measured by iTrace to measure comfort of dry eyes, no scale just review the changes if there are any</description>
  </other_outcome>
  <other_outcome>
    <measure>IOL Master</measure>
    <time_frame>1 month</time_frame>
    <description>as measured by IOL Master 700 to measure comfort of dry eyes, compare the previous images after each visit</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Dextenza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Over the counter Artificial tears</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Intracanalicular Insert</intervention_name>
    <description>all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion</description>
    <arm_group_label>Dextenza</arm_group_label>
    <other_name>dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Over the counter Artificial tears</intervention_name>
    <description>over the counter artificial tears PRN at patient discretion</description>
    <arm_group_label>Over the counter Artificial tears</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:A patient's study eye must meet the following criteria to be eligible
        for inclusion in the study:

          -  Age 18 years and older

          -  Demonstrate objective signs of Ocular Surface Disease (OSD) or

          -  Demonstrate symptoms of OSD determined by a standardized questionnaire

          -  No other corneal pathology to create unknown variability

        Exclusion Criteria:A patient who meets any of the following criteria in either eye will be
        excluded from the study:

          -  History of using topical steroids or other anti-inflammatory drops within 6 months of
             the study

          -  History of corticosteroid implant (Ozurdex or Iluvien) or intravitreal steroid use for
             macular disease in last 12 months

          -  History or current use of oral steroids or immunosuppressants

          -  Active ocular infection

          -  History of HSV

          -  History corneal refractive surgery

          -  Uncontrolled Glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inder P Singh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>President</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pam Lightfield</last_name>
    <phone>(262) 637-0500</phone>
    <phone_ext>5677</phone_ext>
    <email>plightfield@amazingeye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Eye Center of Racine</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Lightfield</last_name>
      <phone>262-637-0500</phone>
      <phone_ext>5677</phone_ext>
      <email>plightfield@amazingeye.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Eye Centers of Racine and Kenosha</investigator_affiliation>
    <investigator_full_name>Pam Lightfield</investigator_full_name>
    <investigator_title>I. Paul Singh, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

